Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LN-145 by Iovance Biotherapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
LN-145 is under clinical development by Iovance Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Lifileucel by Iovance Biotherapeutics for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Lifileucel by Iovance Biotherapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
LN-145 by Iovance Biotherapeutics for Ewing Sarcoma: Likelihood of Approval
LN-145 is under clinical development by Iovance Biotherapeutics and currently in Phase I for Ewing Sarcoma. According to GlobalData, Phase...
LN-145 by Iovance Biotherapeutics for Primary CNS Lymphoma: Likelihood of Approval
LN-145 is under clinical development by Iovance Biotherapeutics and currently in Phase I for Primary CNS Lymphoma. According to GlobalData,...
LN-145 by Iovance Biotherapeutics for Rhabdomyosarcoma: Likelihood of Approval
LN-145 is under clinical development by Iovance Biotherapeutics and currently in Phase I for Rhabdomyosarcoma. According to GlobalData, Phase I...
Lifileucel by Iovance Biotherapeutics for Endometrial Cancer: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Lifileucel by Iovance Biotherapeutics for Primary CNS Lymphoma: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase I for Primary CNS Lymphoma. According to GlobalData,...
Lifileucel by Iovance Biotherapeutics for Rhabdomyosarcoma: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase I for Rhabdomyosarcoma. According to GlobalData, Phase I...
Lifileucel by Iovance Biotherapeutics for Ewing Sarcoma: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase I for Ewing Sarcoma. According to GlobalData, Phase...
IOV-4001 by Iovance Biotherapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
IOV-4001 is under clinical development by Iovance Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
IOV-4001 by Iovance Biotherapeutics for Metastatic Melanoma: Likelihood of Approval
IOV-4001 is under clinical development by Iovance Biotherapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...
Aldesleukin by Iovance Biotherapeutics for Graft Versus Host Disease (GVHD): Likelihood of Approval
Aldesleukin is under clinical development by Iovance Biotherapeutics and currently in Phase II for Graft Versus Host Disease (GVHD). According...